Numbers

The Numbers

Elevance trades at $356 — almost exactly its 20-year average P/E (14x) but at a 20% discount to its 5-year average. The story behind that gap is mechanical: medical loss ratio expansion from Medicaid redetermination, ACA exchange acuity, and elevated Medicare Advantage utilization compressed FY2025 operating margin to 3.33% (from a five-year peak of 5.20%) and crushed cash conversion from 200%+ to 56%. The single number that decides whether this stock re-rates higher or stays trapped is the operating margin trajectory through 2026: a recovery to the long-run 4.5–5% restores normalized EPS to roughly $30+ and pulls fair value into the $440–500 range; a structurally lower 3.5% normalizes EPS near $25 and the current price is roughly fair. Everything below answers a question that maps to that fork.

Where ELV is today

ELV serves roughly 42 million members across commercial, Medicare and Medicaid lines. It is the second-largest US managed care organization by revenue after UnitedHealth, but at a market cap of $80B it is currently valued at just 27% of UNH's $299B — a multi-decade-wide gap driven by the EBITDA-margin spread (4.2% UNH vs 4.2% ELV at the EBITDA line, but UNH's Optum services arm justifies a structurally higher multiple).

Quality Composite — is this business durable?

A scorecard, computed from the underlying financials. Each row is observable; the verdict is the reader's.

Composite read: ~70 / 100. ELV remains a quality compounder by long-run measures (ROE, predictability, Altman Z all strong), but two components are flashing yellow: cash conversion has collapsed from 211% in 2020 to 56% in 2025, and interest coverage has halved as debt rose 60% over the same period. These are cyclical headwinds, not structural breaks — but they're the reason the multiple is compressed.

Revenue and operating earnings — 20-year arc

Revenue compounded at 7.4% annually over 20 years and accelerated to 12.4% over the last 5 (driven by Medicare Advantage growth and Carelon services). But operating income peaked at $7.6B in FY2023 and has fallen 14% to $6.6B in FY2025 — the first sustained decline in a decade. The fan between revenue (up) and operating income (down) is the entire valuation debate.

Margins — the inflection point

Operating margin has compressed in every year since FY2021 — a 187 basis point decline cumulatively. The drivers split roughly 60/40 between Medicaid redetermination losses (post-pandemic acuity normalization) and elevated medical cost trend in Medicare Advantage and ACA exchanges. EBITDA margin at 4.21% is now thinner than it was during the GFC.

Quarterly — the trough may already be in

The quarterly margin pattern is the most informative chart on this page. Three observations: (1) Q4 is structurally the weakest quarter in managed care (claims catch-up); (2) the cycle peak-to-trough swing has widened from ~3pp in 2022 to ~6pp in 2025, signaling cost trend volatility, not a permanent reset; (3) Q1 FY2026 rebounded sharply to 3.99% — early evidence the trough is behind.

Cash generation — earnings are not converting

This is the chart that explains the bear thesis. From FY2020 to FY2023 ELV converted reported net income to free cash flow at 117% on average — meaning every $1 of GAAP earnings produced more than $1 of distributable cash, a hallmark of a quality insurer (working-capital favorable). In FY2025 that ratio collapsed to 56%: $5.66B of NI produced just $3.17B of FCF. Operating cash flow halved. The cause is a working-capital build (medical-claim reserves growing as cost trend reaccelerates) plus higher capex on the Carelon services build-out. Until conversion normalizes, dividends and buybacks have to be funded partly from the balance sheet.

Capex stays disciplined; FCF will follow earnings

Capex intensity stayed at 0.6% of revenue — managed care is not a capital-intensive business. The FCF collapse is therefore not a capex story; it's a working-capital and earnings-quality story.

Capital allocation — disciplined return, but funded by debt

Over 10 years ELV deployed $20.5B on buybacks (retiring 14% of share count, from 262M in 2010 to 225M in 2025), $10.7B on dividends, and $16.3B on acquisitions (CareMore, Beacon, BioPlus, Mosaic Life Care, etc.). Total capital out at $47.5B against $52.4B of FCF earned — a 91% reinvestment ratio. Capital allocation is disciplined, but the FY2024 surge ($2.9B buybacks, $4.8B M&A, $1.5B dividends = $9.2B vs $4.6B FCF) was funded by a $7.7B debt raise. The 2025 $2.6B buyback was effectively debt-funded too.

Balance sheet — leverage is rising, but coverage is fine

Total debt grew from $20B in FY2019 to $32B in FY2025 — a 60% increase used to fund acquisitions and buybacks. ELV remains net-cash (cash and equivalents of $36B exceed total debt of $32B, leaving net debt at negative $4.1B), so the absolute position is fine. The concerning trend is interest coverage: EBIT/interest fell from 8.9x in FY2021 to 4.7x in FY2025, the lowest since 2008. Altman Z at 3.03 keeps the firm in the safe zone.

Valuation — current vs 20-year history (the critical chart)

The picture is mixed depending on which mean you anchor to. P/E at 13.9x is right at the 20-year mean — ELV is "fairly valued" against its full-cycle history. But EV/EBITDA at 8.7x sits 1.2x below the 5-year mean (10.5x) and only +0.36 standard deviations above the 20-year mean — the bond market is pricing this like a regulated utility, not a long-duration compounder. The gap between P/E and EV/EBITDA narratives reveals the trap: depressed earnings make the P/E look reasonable; depressed EBITDA makes the EV/EBITDA also look reasonable. Multiple expansion and earnings recovery have to happen together — or neither happens.

Per-share economics

EPS doubled from $14.19 in 2018 to $25.68 in 2024 (12.6% CAGR), then plateaued in 2025. FCF per share peaked at $38 in FY2020 (pandemic working-capital tailwind) and has fallen 63% to $14.13 — directly proportional to the cash-conversion collapse. Dividends per share have grown every year since the 2014 initiation — an unbroken streak — and the FY2025 payout of $6.83 represents a 27% payout ratio against earnings. Headroom for the dividend is comfortable.

Peer comparison — ELV is the discount value name

ELV's P/E at 13.9x is the cheapest in the peer set after CI — and CI's 12.4x reflects PBM regulatory risk, not insurance fundamentals. UNH commands a 25x premium because Optum services (45% of UNH op income) carry software-like multiples. CVS at 57x is distressed earnings (Aetna underwriting losses). Among pure-play managed care peers (HUM, MOH), ELV trades at half their P/E despite stronger absolute scale and a comparable operating margin profile. The 20% multiple discount to UNH on EV/EBITDA basis (8.7x vs 13.1x) is the largest gap in 15 years.

Valuation positioning — quality vs price

ELV sits in the lower-right quadrant of the peer scatter: high ROE (top-3 in peer set) at the lowest P/E. The "expected" relationship is that higher-ROE businesses carry higher multiples — UNH and HUM violate this only because their Optum/Medicare-Advantage growth stories command an "asset light" premium. ELV's positioning is the textbook cheap-quality trade if you believe the ROE compression is cyclical.

Fair value — three methods, scenario range

Triangulating the methods, base fair value is approximately $400/share — about 12% upside to the current $356 close. The bear case ($300) requires accepting that 3.3% operating margin is the new normal and that the multiple stays at 12x — a double-derate that has happened only once in the past 20 years (2009). The bull case ($500+) requires a return to 5% operating margin in 2026/27 and a 5y-average multiple — both individually plausible, jointly demanding.

What the numbers say

The numbers confirm that ELV is a high-quality managed care franchise with a 20-year track record of compounding revenue at 7%+ and EPS at 11%+, a fortress-grade balance sheet (Altman Z 3.03, net cash of $4B), and disciplined capital allocation that has retired 14% of shares while initiating and growing a dividend. The numbers contradict the surface bear narrative that ELV is "cheap for a reason": the 20-year P/E is 14x, the stock trades at 14x — there is no permanent valuation discount, just a cyclical earnings trough. What to watch next quarter is the medical loss ratio sequencing — Q1 FY2026 already showed operating margin recovering to 3.99% from Q4 FY2025's 0.29%; if Q2 holds above 4% and Q3 stays above 3%, the 2025 trough is in and the path to a $30 mid-cycle EPS reopens. If Q2 instead reverts to the Q4 pattern, the bear case (margins are structural, not cyclical) gets one big additional data point.